Mobile

A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000511-25

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the effectiveness of AMG 162 in reducing urinary N-telopeptide (uNTx) below 50 nM BCE / mM creatinine in advanced cancer subjects with bone metastases (including multiple myeloma subjects with bone disease) with uNTx levels above 50 nM BCE / mM creatinine during intravenous bisphosphonate treatment.

Critère d'inclusion

  • Bone metastases of solid tumors (except lung) or multiple myeloma bone disease

Liens